ZymoGenetics commences Phase 2B study of PEG-Interferon lambda in hepatitis C

[Guest guest]

ZymoGenetics commences Phase 2B study of PEG-Interferon lambda in hepatitis C

ZymoGenetics, Inc. today announced the initiation of the second part of a Phase

2 clinical trial with PEG-Interferon lambda (IL-29) and ribavirin in

treatment-naïve patients with chronic hepatitis C virus (HCV) infection.

ZymoGenetics is developing the investigational compound PEG-Interferon lambda in

collaboration with Bristol-Myers Squibb Company.

http://www.news-medical.net/news/20100602/ZymoGenetics-commences-Phase-2B-study-\

of-PEG-Interferon-lambda-in-hepatitis-C.aspx

_________________________________________________________________

Hotmail is redefining busy with tools for the New Busy. Get more from your

inbox.

http://www.windowslive.com/campaign/thenewbusy?ocid=PID28326::T:WLMTAGL:ON:WL:en\

-US:WM_HMP:042010_2

[Guest guest]

ZymoGenetics commences Phase 2B study of PEG-Interferon lambda in hepatitis C

ZymoGenetics, Inc. today announced the initiation of the second part of a Phase

2 clinical trial with PEG-Interferon lambda (IL-29) and ribavirin in

treatment-naïve patients with chronic hepatitis C virus (HCV) infection.

ZymoGenetics is developing the investigational compound PEG-Interferon lambda in

collaboration with Bristol-Myers Squibb Company.

http://www.news-medical.net/news/20100602/ZymoGenetics-commences-Phase-2B-study-\

of-PEG-Interferon-lambda-in-hepatitis-C.aspx

_________________________________________________________________

Hotmail is redefining busy with tools for the New Busy. Get more from your

inbox.

http://www.windowslive.com/campaign/thenewbusy?ocid=PID28326::T:WLMTAGL:ON:WL:en\

-US:WM_HMP:042010_2

[Guest guest]

ZymoGenetics commences Phase 2B study of PEG-Interferon lambda in hepatitis C

ZymoGenetics, Inc. today announced the initiation of the second part of a Phase

2 clinical trial with PEG-Interferon lambda (IL-29) and ribavirin in

treatment-naïve patients with chronic hepatitis C virus (HCV) infection.

ZymoGenetics is developing the investigational compound PEG-Interferon lambda in

collaboration with Bristol-Myers Squibb Company.

http://www.news-medical.net/news/20100602/ZymoGenetics-commences-Phase-2B-study-\

of-PEG-Interferon-lambda-in-hepatitis-C.aspx

_________________________________________________________________

Hotmail is redefining busy with tools for the New Busy. Get more from your

inbox.

http://www.windowslive.com/campaign/thenewbusy?ocid=PID28326::T:WLMTAGL:ON:WL:en\

-US:WM_HMP:042010_2

[Guest guest]

ZymoGenetics commences Phase 2B study of PEG-Interferon lambda in hepatitis C

ZymoGenetics, Inc. today announced the initiation of the second part of a Phase

2 clinical trial with PEG-Interferon lambda (IL-29) and ribavirin in

treatment-naïve patients with chronic hepatitis C virus (HCV) infection.

ZymoGenetics is developing the investigational compound PEG-Interferon lambda in

collaboration with Bristol-Myers Squibb Company.

http://www.news-medical.net/news/20100602/ZymoGenetics-commences-Phase-2B-study-\

of-PEG-Interferon-lambda-in-hepatitis-C.aspx

_________________________________________________________________

Hotmail is redefining busy with tools for the New Busy. Get more from your

inbox.

http://www.windowslive.com/campaign/thenewbusy?ocid=PID28326::T:WLMTAGL:ON:WL:en\

-US:WM_HMP:042010_2